Title: L1CAM in Early-Stage Type I Endometrial Cancer: Results of a Large Multicenter Evaluation
Authors: Zeimet, Alain G ×
Reimer, Daniel
Huszar, Monica
Winterhoff, Boris
Puistola, Ulla
Abdel Azim, Samira
Müller-Holzner, Elisabeth
Ben-Arie, Alon
van Kempen, Léon C
Petru, Edgar
Jahn, Stephan
Geels, Yvette P
Massuger, Leon F
Amant, Frédéric
Polterauer, Stephan
Lappi-Blanco, Elisa
Bulten, Johan
Meuter, Alexandra
Tanouye, Staci
Oppelt, Peter
Stroh-Weigert, Monika
Reinthaller, Alexander
Mariani, Andrea
Hackl, Werner
Netzer, Michael
Schirmer, Uwe
Vergote, Ignace
Altevogt, Peter
Marth, Christian
Fogel, Mina #
Issue Date: Aug-2013
Publisher: Oxford University Press
Series Title: Journal of the National Cancer Institute vol:105 issue:15 pages:1142-1150
Abstract: BACKGROUND: Despite the excellent prognosis of Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) stage I, type I endometrial cancers, a substantial number of patients experience recurrence and die from this disease. We analyzed the value of immunohistochemical L1CAM determination to predict clinical outcome. METHODS: We conducted a retrospective multicenter cohort study to determine expression of L1CAM by immunohistochemistry in 1021 endometrial cancer specimens. The Kaplan-Meier method and Cox proportional hazard model were applied for survival and multivariable analyses. A machine-learning approach was used to validate variables for predicting recurrence and death. RESULTS: Of 1021 included cancers, 17.7% were rated L1CAM-positive. Of these L1CAM-positive cancers, 51.4% recurred during follow-up compared with 2.9% L1CAM-negative cancers. Patients bearing L1CAM-positive cancers had poorer disease-free and overall survival (two-sided Log-rank P < .001). Multivariable analyses revealed an increase in the likelihood of recurrence (hazard ratio [HR] = 16.33; 95% confidence interval [CI] = 10.55 to 25.28) and death (HR = 15.01; 95% CI = 9.28 to 24.26). In the L1CAM-negative cancers FIGO stage I subdivision, grading and risk assessment were irrelevant for predicting disease-free and overall survival. The prognostic relevance of these parameters was related strictly to L1CAM positivity. A classification and regression decision tree (CRT)identified L1CAM as the best variable for predicting recurrence (sensitivity = 0.74; specificity = 0.91) and death (sensitivity = 0.77; specificity = 0.89). CONCLUSIONS: To our knowledge, L1CAM has been shown to be the best-ever published prognostic factor in FIGO stage I, type I endometrial cancers and shows clear superiority over the standardly used multifactor risk score. L1CAM expression in type I cancers indicates the need for adjuvant treatment. This adhesion molecule might serve as a treatment target for the fully humanized anti-L1CAM antibody currently under development for clinical use.
ISSN: 0027-8874
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Gynaecological Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science